A cell culture system" 2 in which human bone marrow responds to the in vitro addition of erythropoietin with increased heme synthesis provides a new means of studying disorders of red cell production, and has already been used to study the erythropoietic response of marrow from patients with polycythemia vera.3 This method should also prove useful in the investigation of those diseases of underproduction of red cells where enough marrow can be obtained to perform the study. Such a disease is pure red cell aplasia in which the marrow has a normal cellularity with only a deficient number of red cell precursors. Several investigators4-7 have suggested that this disease is due to an autoimmune state, but little evidence of a circulating inhibitor to erythropoiesis has so far been presented. Our studies of a patient with red cell aplasia show that his marrow not only responds to added erythropoietin in vitro with an increased rate of heme synthesis, but also develops an enhanced control level of heme synthesis when separated from high concentrations of his plasma. In addition, the patient's plasma inhibits heme synthesis of normal marrow in vitro, and contains an antibody to erythroblast nuclei. These findings, taken with the patient's recovery to a normal state after treatment with 6-mercaptopurine, an immunosuppressive agent, all lend support to the idea that this disease may be due to a circulating antibody.
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Materials and Methods.-The patient (M. E.) was a 45-year-old white male from San Jose, Costa Rica, who was well until September 1962, when progressive anemia was first noted. He took no medications up to this time, and the only contacts with toxic agents were an exposure to insecticides for 7 years and to dinitrophenol for 4 months. Laboratory tests revealed a normochromic, normocytic anemia with a complete absence of reticulocytes in the peripheral blood. Platelet and white cell counts were normal. Bone marrow aspiration showed an almost complete absence of normoblasts. The patient was treated with 100 ltg of vitamin B,2 intramuscularly (IM) each day for 1 month; then folic acid, 15 mg/day, for 2 weeks; then depo-testosterone, 100 mg IM every 15 days, and prednisone, 40 mg/day, for 2 months; then vitamin B6, 50 mg IM, and prednisone, 10 mg, for 7 months. During this latter period, in June 1964, he had a splenectomy which revealed a normal spleen. The patient then received oxymetholone, 100 mg daily, for 6 months; then cobalt IM daily for 1 month; then riboflavin, 20 mg by mouth, for a similar period. Neither the above medications nor the splenectomy helped his anemia so that during this period he received several units of blood every 4 to 5 weeks.
In January 1966 he was referred to the University of Chicago Hospitals. Physical examination revealed a short, lean man who appeared chronically ill. A darkened skin and mild hepatomegaly were the only positive physical findings. The blood picture showed a severe anemia without any reticulocytes, a white cell count of 6,850 cells/mm3 with a normal differential smear, and a platelet count of 510,100 cells/mm'. Smears and sections8 revealed a slightly hypercellular bone marrow with normal white cell and platelet precursors but a marked decrease in red cell precursors. Results.-When the marrow from this patient was incubated in 20 per cent normal human plasma with erythropoietin, the rate of heme synthesis increased threefold above the rate of the untreated cells by 72 hours (Fig. 1) . Moreover, the rate of heme synthesis of the untreated controls, which has repeatedly declined with other bone marrows," 2 increased twofold by 66-72 hours as compared to 0-6 hours.
This increase in the controls could be due to residual endogenous erythropoietin, but we have never observed it in marrow from other patients with hemolytic anemias incubated under the same conditions. When the same marrow was incubated in 20 per cent of the patient's own plasma, the controls without erythropoietin increased to a greater rate by 66-72 hours than with incubation in normal plasma, and addition of erythropoietin had no effect. This was probably because the erythropoietic titer of the patient's plasma was From these data it appeared that the marrow was either freed from some in vivo inhibitory factor or that a new essential factor was supplied in the in vitro medium. The patient's marrow was therefore incubated in 89 per cent of his own plasma and in 33 per cent of his own plasma diluted with Hanks' salt 12 In another experiment with the patient's marrow a normal plasma control was run: Increased concentrations of normal plasma did not inhibit the rate of heme synthesis, but a high concentration of the patient's plasma was associated with a When the rate of heme synthesis of the patient's marrow was tested with high concentrations of his plasma at 0-6 hours and at 72-78 hours, the inhibitory effect was only observed at the later time (Fig. 3) . This also occurred when his plasma was added to normal marrow. The increased concentrations of the patient's plasma therefore did not inhibit heme synthesis already in progress, but prevented the increase in the rate of heme synthesis observed 72-78 hours later. Thus the plasma inhibitor is apparently not a simple chemical inhibitor of heme synthesis but probably acts to prevent the later effects of erythropoietin on increased heme synthesis.
Because of the possibility that this inhibitor was an antibody, purified IgG globulins were prepared from the patient's plasma (Fig. 4) and conjugated with fluorescein isothiocyanate. This conjugated globulin caused an apple-green speckled fluorescence of many round nuclei in normal marrow cells (Fig. 5A ). When these cells were counterstained with Wright-Giemsa, they were easily identified as erythroblasts (Fig. 5B) . The leukocyte precursors showed only a green cytoplasmic fluorescence, perhaps due to antibodies formed through frequent blood transfusions, while fresh cryostat sections of liver and lymph nodes, and lymph node imprints, showed no green nuclear fluorescence. Additional controls consisted of an unstained bone marrow smear, one pretreated with the patient's unlabeled IgG and then stained with the fluoresceinated IgG, and a bone marrow smear stained with a similarly prepared, fluorescein-labeled IgG from normal plasma. None of these showed the green nuclear fluorescence, demonstrating the specificity of the reaction between the patient's conjugated IgG and erythroblast nuclei. This inhibition could be due to an action on the hormone itself, but it is difficult to explain how dilultion of the patient's plasma whould allows erythropoiesis The idea that an antibody to marrow cells might cause this disease is not new, since a high association of red cell aplasia with thymoma has been reported, and in one fourth of these cases thymectomy has resulted in disappearance of the disease.4 Because the thymoma cells did not invade the bone marrow locally, they were thought to act via a circulating plasma factor, although this was never demonstrated. In 1949 Smith reported a case of pure red cell aplasia in a newborn associated with the formation of an anti-A agglutinin made by the mother in an incompatible pregnancy, and he postulated that this might be the cause of the red cell aplasia.7 Eisemann and Dameshek5 and Gasser6 have noted the occurrence of red cell aplasia with autoimmune hemolytic anemia and have postulated an extension of the antibody action on the red cells to the red cell precursors. The former authors reported the disappearance of both after splenectomy.5 Entwistle et al. 16 found a circulating plasma inhibitor to the erythropoiesis of rabbits in a man with red cell aplasia and a carcinoma of the bronchus. This inhibition disappeared with resection of the carcinoma but was never fully characterized. Jepson and Lowenstein"7 demonstrated a plasma inhibitor to mouse erythropoiesis in two patients with red cell aplasia and postulated that this might be an anti-erythropoietin, but their data can equally well be interpreted as the production of an antimarrow factor. Holborow et al.'8 and Barnes19 have described antinuclear factors in several patients with thymoma and refractory anemia but the functional specificity of these factors has not been determined. Professor Barnes has recently indicated20 that he may be able to demonstrate an in vitro immunoglobulin inhibitor of erythropoiesis in patients with refractory anemia. Finally, several authors have injected animal marrow from one species into another to produce an antimarrow serum.21-23 When they then injected this antimarrow serum into the marrow donor species, a marrow aplasia occurred, suggesting that the production of an antimarrow factor could produce red cell aplasia. These studies were never extended to the complete characterization of an antibody or to human disease. Therefore, despite a consistent idea and much work, an antimarrow antibody has never been proved to be the cause of red cell aplasia.
Our studies describe the application of a marrow cell culture system to a particular disease, and show that this system may be very useful in deciding whether red cell aplasia is due to an anti-marrow cell antibody. This would not mean that all red cell aplasias must be due to the same cause. Certainly anti-erythropoietin antibodies have been demonstrated with mice24 and could arise spontaneously in humans. Also metabolic deficiencies specific to red cell precursors might occur which could cause this disease, so that red cell aplasia may be due to different causes in different cases just as there are different causes of hemolytic anemia. Nor should every plasma that inhibits heme synthesis in vitro necessarily be implicated as the cause of the patient's disease, since tissue culture systems are notoriously sensitive to extraneous, nonspecific factors. The positive finding of increased heme synthesis by the marrow with time of incubation in vitro may be a more reliable index of the patient's disease when coupled with the demonstration of a plasma inhibitor to this increase of heme synthesis. VOL. 58, 1967 
